6.54
Precision Biosciences Inc stock is traded at $6.54, with a volume of 237.80K.
It is up +1.08% in the last 24 hours and up +63.91% over the past month.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
See More
Previous Close:
$6.47
Open:
$6.4
24h Volume:
237.80K
Relative Volume:
0.87
Market Cap:
$161.71M
Revenue:
$34.26M
Net Income/Loss:
$-46.61M
P/E Ratio:
-1.2624
EPS:
-5.1806
Net Cash Flow:
$-62.01M
1W Performance:
-2.68%
1M Performance:
+63.91%
6M Performance:
+29.25%
1Y Performance:
+44.37%
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
DTIL
Precision Biosciences Inc
|
6.54 | 159.98M | 34.26M | -46.61M | -62.01M | -5.1806 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
|
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
Precision BioSciences Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
VIX Spike: How does Precision BioSciences Inc compare to its peersQuarterly Risk Review & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Decliners Report: Is Rafael Holdings Inc Equity Warrant stock a good dividend stockProduct Launch & Safe Swing Trade Setups - baoquankhu1.vn
Meme Stocks: What is the PEG ratio of Precision BioSciences Inc2026 Opening Moves & Risk Managed Investment Strategies - baoquankhu1.vn
Precision BioSciences (DTIL) Expected to Announce Earnings on Tuesday - MarketBeat
Q1 EPS Estimate for Precision BioSciences Raised by Analyst - MarketBeat
Is Precision BioSciences Inc stock trending bullishWeekly Loss Report & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
If You Invested $1,000 in Precision Biosciences (DTIL) - Stock Titan
Growth Value: How does Precision BioSciences Inc compare to its peers2026 Institutional Moves & AI Driven Stock Movement Reports - baoquankhu1.vn
Brokers Set Expectations for DTIL Q1 Earnings - MarketBeat
ETFs Investing in Precision BioSciences, Inc. Stocks - TradingView
DTIL Stock Price, Quote & Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Portfolio Recap: Is Precision BioSciences Inc likely to announce a buybackTrade Risk Summary & High Return Stock Watch Alerts - baoquankhu1.vn
Precision BioSciences, Inc. (DTIL) Shareholder/Analyst CallSlideshow (NASDAQ:DTIL) 2026-03-18 - Seeking Alpha
Jones Trading reiterates Precision BioSciences stock rating on DMD trial design - Investing.com Canada
Jones Trading reiterates Precision BioSciences stock rating on DMD trial design By Investing.com - Investing.com South Africa
Precision BioSciences Announces PBGENE-DMD Investor Update and Highlights ARCUS Gene Editing Platform – March 2026 - Minichart
Precision BioSciences Highlights PBGENE-DMD Program and Trial - TipRanks
PBGENE-DMD gene editing strategy at Precision BioSciences (NASDAQ: DTIL) - Stock Titan
Quarterly Risk: How volatile is Precision BioSciences Inc stockEarnings Overview Report & Daily Stock Trend Watchlist - baoquankhu1.vn
Precision BioSciences (DTIL) surpasses Q4 earnings and revenue estimates - MSN
Precision BioSciences (DTIL) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Precision BioSciences Stock (ISIN: US74019P1084) Surges on Q4 Profit Turnaround Amid Analyst Upgrade - AD HOC NEWS
Precision BioSciences Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Australia
Precision BioSciences (NASDAQ:DTIL) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Precision BioSciences (DTIL) Q4 Profit Of US$19.2m Challenges Ongoing Loss Narrative - simplywall.st
Precision BioSciences Inc buy Jefferies Financial Group Inc. - sharewise.com
Jefferies cuts Precision BioSciences stock price target on valuation By Investing.com - Investing.com Australia
DTIL SEC FilingsPrecision Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Jefferies cuts Precision BioSciences stock price target on valuation - Investing.com
Precision BioSciences Advances PBGENE-DMD Trial, Putting New Focus on Duchenne Gene Therapy - TipRanks
Precision BioSciences (NASDAQ:DTIL) Trading Up 12.1%Here's Why - MarketBeat
Precision BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Precision BioSciences (DTIL) Swings to $1.05 EPS in Q4, Reversing $2.22 Year-Ago Loss - AlphaStreet
Precision BioSciences (DTIL) Exceeds Expectations for Q4 Earnings and Revenue - Bitget
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Bus - PharmiWeb.com
Precision BioSciences presents preclinical data on DMD therapy By Investing.com - Investing.com Nigeria
Precision BioSciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update - BioSpace
Precision BioSciences (DTIL) Surpasses Q4 Revenue Expectations - GuruFocus
Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Surges After Strong Q4 Earnings Bea - GuruFocus
Precision BioSciences Q4 2025 Earnings: $20.1M Profit on $34.2M RevenueNews and Statistics - IndexBox
Precision Biosciences 2025 10-K: Revenue $34.3M, GAAP net loss $(45.7M) - TradingView
Precision BioSciences (NASDAQ: DTIL) turns Q4 profit and extends cash runway to 2028 - Stock Titan
Precision BioSciences: Q4 Earnings Snapshot - Barchart.com
Precision BioSciences receives patent allowances for hepatitis B program By Investing.com - Investing.com Canada
Precision BioSciences (DTIL) Secures Key Patent Allowances for P - GuruFocus
Precision BioSciences receives patent allowances for hepatitis B program - Investing.com Australia
Precision BioSciences, Inc. Receives U.S. Patent Allowances Covering PBGENE-HBV Program - marketscreener.com
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program - BioSpace
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):